Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02093546 | Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 | completed | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01870947 | Assisted Exercise in Obese Endometrial Cancer Patients | completed | N/A | 95 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2020 |
| NCT01846520 | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | completed | N/A | 200 | City of Hope Medical CenterOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03540407 | Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | completed | Phase 2 | 66 | Catalysis SLINDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT04224467 | The Application of Real-Time Near-infrared Imaging in Gynecological Surgery | unknown | N/A | 500 | Chen ChunlinOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03379376 | EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery | completed | N/A | 10 | Wake Forest University Health SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04191252 | Genetic Mutation in Epithelial Ovarian Cancer | unknown | — | 500 | Lei LiOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT04190667 | Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer | unknown | — | 1,300 | Lei LiOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01991808 | Suitability of DCE-MRI for Detection of Vascular Changes After VBT | completed | N/A | 16 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | terminated | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00445887 | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer | completed | Phase 2 | 60 | Gynecologic Oncology GroupNETWORK | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02096783 | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | completed | N/A | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03373058 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery(EHTASEOCCS) | unknown | Phase 3 | 310 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03220932 | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer(HIPOVA-01) | unknown | Phase 3 | 132 | Hospices Civils de LyonOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT02115477 | Lymphedema After Primary Surgery for Endometrial Cancer(LASEC) | completed | — | 262 | Preben Kjolhede, MD, professorOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT03754569 | Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer(MicroPCI) | completed | N/A | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)(PIPACRegis) | unknown | — | 1,000 | Sabine RhodeOTHER | 13 | Oct 8, 2019 | clinicaltrials |
| NCT04101760 | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer | unknown | Phase 3 | 200 | Lei LiOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 297 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02376231 | To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study(PJEOC) | completed | N/A | 120 | Dr Thumuluru Kavitha MadhuriOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03302884 | Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma(CIDOC) | unknown | N/A | 150 | Institut Paoli-CalmettesOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03888599 | Knowledge and Attitudes Towards Human Papillomavirus Infections and HPV Vaccination | completed | — | 600 | University Hospital, GenevaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT02578888 | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | completed | N/A | 95 | Albert Einstein College of MedicineOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | recruiting | Phase 3 | 360 | Japanese Gynecologic Oncology GroupOTHER | 2 | Aug 30, 2019 | clinicaltrials |
| NCT01504126 | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT02520115 | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | completed | Phase 1 | 50 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT01132820 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01196429 | Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 3 | Aug 8, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04001023 | Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia(OVANOX) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01747798 | Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 10 | Mayo ClinicOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT00006089 | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2019 | clinicaltrials |
| NCT00023712 | Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00041080 | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 139 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00022659 | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025155 | Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025233 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00053365 | Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00095979 | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00096447 | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00113373 | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00301964 | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00429793 | Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2020source: clinicaltrials